11:15 AM EDT, 04/03/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said Wednesday it has started a phase 2 study of ALTO-203 in major depressive disorder patients.

Alto said it expects to enroll about 60 adult participants with MDD and anhedonia, with top-line data expected in H1 of 2025.

The company said ALTO-203 showed a favorable tolerability profile across three phase 1 trials and produced a variety of emotional and brain effects that support its antidepressant potential.

Price: 14.17, Change: +0.06, Percent Change: +0.43